Mechlorethamine
Mustargen · Alkylating agent (nitrogen mustard)
Tumor lysis in bulky lymphoma is the main renal hazard; modern topical gel has no detectable systemic absorption.
Topoisomerase II inhibitor (acridine)
Amsidine · mAMSA
Topoisomerase II inhibitor (acridine) · approved 1987 · 4 citations
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
Acridine topoisomerase II inhibitor for refractory AML; renal clearance is minor and the kidney-relevant risk is tumor lysis, while elimination is chiefly hepatobiliary.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Direct nephrotoxicity is not a prominent feature. The main renal hazard is tumor lysis syndrome during leukemia induction/salvage; incidence specific to amsacrine is not quantified. Pharmacokinetic studies show renal elimination plays only a minor role, with clearance dominated by hepatic metabolism and biliary excretion.Source: Jurlina et al., Cancer Chemother Pharmacol 1985 (renal elimination minor); not quantified
Tumor lysis within hours to days of effective cytoreduction.
Distilled from: “TLS within hours to days of effective cytoreduction.”
This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Renal electrolyte derangement — magnesium/potassium/calcium wasting (cisplatin, anti-EGFR antibodies) or retention (FGFR-inhibitor hyperphosphatemia, tumor-lysis hyperkalemia/hyperphosphatemia).
Intratubular precipitation of drug or metabolite — high-dose methotrexate and tumor lysis crystals.
Aminoacridine derivative that intercalates DNA and inhibits topoisomerase II, stabilizing cleavable complexes and producing protein-associated DNA strand breaks that trigger apoptosis in leukemic cells.
Tubular Lumen
The urine flow path
Proximal Tubule
Bulk reabsorption + drug uptake (OCT2, OATs)
Class-level context for the major non-renal toxicities of the Topoisomerase II inhibitor (acridine) class.
Neurologic
Neuropathy, encephalopathy, ICANS, PRES
Hematologic
Cytopenias, thrombosis, TMA
Immune / Infusion
CRS, infusion reactions, irAEs, anaphylaxis
4 primary references — trials, cohorts, mechanism, and reviews. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Everything below is FAERS — adverse events someone chose to report, about 538 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.
What reporting says about this profile's documented lesions
Counted by the report's active-substance field, which FAERS fills almost only on reports received from 2013 on, so these figures describe reports since then, not the agent's whole history.
Reported with a death outcome
199 of 538 reports
Reported with hospitalization
188 of 538 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial · 22 of the 538 reports predate 2015 and are not drawn.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Amsacrine sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Mustargen · Alkylating agent (nitrogen mustard)
Tumor lysis in bulky lymphoma is the main renal hazard; modern topical gel has no detectable systemic absorption.
Truseltiq · FGFR inhibitor
Hyperphosphatemia — on-target FGFR class effect; nephrocalcinosis risk.
Zepzelca · Marine alkylating agent
Rhabdomyolysis risk in small-cell lung cancer.
Etopophos · Topoisomerase II inhibitor
Tumor lysis; renally cleared.
Treanda · Alkylator
Tumor lysis-mediated AKI is the principal risk; TMA is rare.
Fludara · Purine analog
Tumor lysis; accumulates in renal impairment.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.